PYRIDOSTIGMINE BROMIDE (pyridostigmine bromide) by Medica Corp is inhibitor. First approved in 2003.
Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
Pyridostigmine bromide is an oral acetylcholinesterase inhibitor approved in 2003. It works by inhibiting the breakdown of acetylcholine, increasing neuromuscular transmission. The drug is primarily used in myasthenia gravis and related neuromuscular disorders.
Product approaching loss of exclusivity with moderate competitive pressure (30%), signaling potential team consolidation and shift toward managed decline strategies.
inhibitor.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
With zero linked job openings and LOE approaching, career opportunities on this product are contracting. Professionals should expect this role to serve as a maintenance assignment rather than a growth-focused opportunity, with potential transitions to pipeline or post-LOE generic strategy roles.
Worked on PYRIDOSTIGMINE BROMIDE at Medica Corp? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.